Evidence map›Paper›PMID 36385507›Full record

ArticleCancer science2023

Discovery of novel DNA-damaging agents through phenotypic screening for DNA double-strand break.

Doudou Zhang, Takashi Shimokawa, Qianqian Guo, Shingo Dan, Yoshio Miki, Shigeaki Sunada

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Doudou ZhangDepartment of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Takashi ShimokawaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID https://orcid.org/0000-0001-6549-9277
Qianqian GuoDepartment of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Shingo DanDivision of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0022-2725
Yoshio MikiDepartment of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Shigeaki SunadaDepartment of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9446-8522
Tokyo Medical and Dental University · JPJapanese Foundation For Cancer Research · JPNational Institutes for Quantum Science and Technology · JP

Funding

Japan Agency for Medical Research and Development JP19mk0101168Japan Society for the Promotion of Science JP16H06276Japan Society for the Promotion of Science JP20H04333Ministry of Education, Culture, Sports, Science and Technology JPMXS0320210041
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) seriously damage DNA and promote genomic instability that can lead to cell death. They are the source of conditions such as carcinogenesis and aging, but also have important applications in cancer therapy. Therefore, rapid detection and quantification of DSBs in cells are necessary for identifying carcinogenic and anticancer factors. In this study, we detected DSBs using a flow cytometry-based high-throughput method to analyze γH2AX intensity. We screened a chemical library containing 9600 compounds and detected multiple DNA-damaging compounds, although we could not identify mechanisms of action through this procedure. Thus, we also profiled a representative compound with the highest DSB potential, DNA-damaging agent-1 (DDA-1), using a bioinformatics-based method we termed "molecular profiling." Prediction and verification analysis revealed DDA-1 as a potential inhibitor of topoisomerase IIα, different from known inhibitors such as etoposide and doxorubicin. Additional investigation of DDA-1 analogs and xenograft models suggested that DDA-1 is a potential anticancer drug. In conclusion, our findings established that combining high-throughput DSB detection and molecular profiling to undertake phenotypic analysis is a viable method for efficient identification of novel DNA-damaging compounds for clinical applications.

Indexed as

Antineoplastic AgentsDNA Breaks, Double-StrandedDNADNA DamageDNA RepairEtoposideHistonesHumansAntineoplastic AgentsDNAEtoposideHistonesbioinformaticsDNA double-strand breakdrug screeningtopoisomerase II inhibitorγH2AX

Identifiers

PMID36385507
PMCPMC9986057
OpenAlexW4309245119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.